Vosaroxin - Sunesis Pharmaceuticals

Drug Profile

Vosaroxin - Sunesis Pharmaceuticals

Alternative Names: AG-7352; AG-7352 hydrochloride; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Quinolones; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Ovarian cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 16 Nov 2017 University of Ulm and Sunesis Pharmaceuticals plan a phase II trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy, In adults, In the elderly, Newly diagnosed) in Germany in December 2017 (NCT03338348)
  • 22 Aug 2017 Indiana University School of Medicine terminates a clinical trial in Acute myeloid leukaemia (In the elderly, First-line therapy, Combination therapy) in USA due to safety concerns (NCT02485353)
  • 23 Jun 2017 Efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndrome released by Sunesis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top